Introduction

Lung tumors with neuroendocrine morphology by light microscopy consist of a spectrum of tumor types with different biology and clinical features. The morphologic types include low-grade typical carcinoid, intermediate-grade atypical carcinoid and high-grade neuroendocrine carcinomas that are further classified into large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC). Growing evidence suggests that carcinoid tumors are biologically distinct from high-grade neuroendocrine carcinomas given the significant differences in clinical behavior and molecular alterations as well as possible precursor lesions and association with other histologic types between the two groups (1-5).

Of the high-grade neuroendocrine carcinomas, SCLC harbors a distinct biology and clinical course. SCLC is found almost exclusively in smokers and has a rapid doubling time and a more aggressive clinical course than non-small cell lung cancer (NSCLC), with the majority presenting at stage IV. Interestingly, Govindan et al., using the surveillance, epidemiology and end results database,
have reported a decrease in the incidence of SCLC (as a percentage of the number of patients diagnosed with all types of lung cancer) from 17.26% in 1986 to 12.95% in 2002 (6). While a decrease in the incidence of smoking and the change to low-tar filter cigarettes likely contribute to the decreasing incidences of SCLC, they may be attributed in part to how pathologists distinguish between SCLC and NSCLC, in particular LCNEC (7).

Pathological diagnosis of LCNEC is challenging in some cases, and it is essentially diagnosed on resected specimens. The incidence of LCNEC is very low and has been reported to range from 2.4% to 3.1% in resected lung cancers (8,9). Patients with LCNEC are predominantly male (8,10), older, and heavy smokers (8,9). All-stage 5-year overall survival for LCNEC ranges from 13% to 57% (11), and the prognosis of LCNEC is comparable to that of SCLC (10,12). Even patients with pathologic stage IA LCNEC treated by complete resection have worse outcomes than those with non-neuroendocrine NSCLC (13). However, optimal therapy for advanced LCNEC has not been defined yet. Several studies have evaluated response to chemotherapy and/or radiation in patients with advanced LCNEC, the diagnosis of which was made on biopsy samples, leading to conflicting results as to whether LCNEC is responsive to platinum/etoposide that is typically effective for SCLC (14-18). It may be explained by biological heterogeneity of LCNEC that has been elucidated by the recent molecular studies revealing a few subsets in LCNEC (19,20). In this review, we will discuss the clinical, pathological, and molecular aspects of LCNEC to elucidate its heterogeneous nature.

**Pathological features**

Histologically, LCNEC is defined as a non-small cell carcinoma with neuroendocrine morphology including organoid or trabecular patterns, rosette-like structures or peripheral palisading, as well as neuroendocrine differentiation confirmed by immunohistochemistry and/or electron microscopy (Figure 1) (21). Tumor cells are typically greater than 3 times the diameter of resting lymphocytes and exhibit moderate, often eosinophilic, cytoplasm and prominent nuclei (22,23). Mitotic activity is usually brisk (21), and large areas of necrosis are typically seen. One unequivocally positive neuroendocrine marker (synaptophysin, chromogranin A or CD56) is sufficient to confirm the diagnosis, but CD56 expression alone must be interpreted with caution (24-26). The differentiation of LCNEC from its mimickers, including small cell carcinoma, atypical carcinoid, and NSCLC, can be challenging, in particular in biopsy/cytology specimens. Thus the diagnosis of LCNEC can only be made in resection specimens, while it could be suggested in the small samples.

**SCLC vs. LCNEC**

The classic neuroendocrine morphology may be seen in SCLC, but is uncommon, in particular, on the small biopsies typically obtained from these patients. The latter often exhibit a sheet-like growth without the neuroendocrine morphology. Tumor cells of SCLC are round, oval, or spindle-shaped; they usually are less than the size of three small resting lymphocytes in biopsy specimens, but there is no absolute cutoff for tumor cell size and they often appear larger in resection specimens (27-29). More importantly, SCLC is characterized by scant cytoplasm, a high N/C ratio, finely granular chromatin, and absent or inconspicuous nucleoli (Figure 2). The mitotic rate is high and averages over 60 mitoses per 2 mm² (27,28). Necrosis is common and often extensive. Basophilic staining of vascular walls due to encrustation by DNA from necrotic tumor cells (the Azzopardi phenomenon) is frequent in areas of necrosis. If tumor cells with conspicuous nucleoli or pleomorphic giant tumor cells are identified, these are interpreted as large cell carcinoma elements, and when these constitute 10% or more of the tumor volume, the tumor is diagnosed as combined small cell and LCNEC (28,29).

Although typical LCNEC is morphologically distinct from SCLC, the differentiation between LCNEC and
SCLC can be difficult in some cases. In the study by Travis et al. in which surgically resected neuroendocrine tumors of the lung were reviewed independently by five pulmonary pathologists, there was unanimous diagnostic agreement only on 70% of SCLCs and 40% of LCNECs, and most of disagreements fell between LCNEC and SCLC (31). They are characterized by tumor cells with a relatively small amount of cytoplasm, a high N/C ratio, finely granular chromatin, and small or inconspicuous nucleoli (features of SCLC) and a polygonal shape, large nuclei and organoid, trabecular, palisading patterns, and/or a rosette-arrangement (features of LCNEC) (Figure 3). A morphometric study confirmed that tumor nuclear diameter/lymphocyte size (T/L) ratios of the borderline category (2.91±0.76) fell between those of SCLC (2.62±0.90) and LCNEC (3.22±0.86) (31,32). Interestingly, borderline high-grade neuroendocrine carcinomas have a CD56+, mASH1+, chromogranin A-, synaptophysin-immunophenotype, and TTF-1 tends to be negative (31).

Asamura et al. also reported 14 borderline high-grade neuroendocrine carcinomas, which comprised 5.5% of the 254 high-grade neuroendocrine carcinomas in their multi-institutional study (10). We hypothesize that the presence of borderline high-grade neuroendocrine carcinomas contributes to the discordant classification of high-grade neuroendocrine carcinomas among pathologists (31-33). Some pathologists may classify borderline high-grade neuroendocrine carcinomas as SCLC based on the high N/C ratio and the relatively scant cytoplasm. For example, Figure 10 in the article by Nicholson et al. represents borderline high-grade neuroendocrine carcinoma according to our criteria, but they diagnosed it as SCLC (29). Conversely, some pathologists may classify the same case as LCNEC based on the polygonal shape of tumor cells, larger nuclei, and conspicuous nucleoli.

Atypical carcinoid tumor vs. LCNEC

While the majority of carcinoid tumors harbor low mitotic rates that fall in the range defined by the WHO classification (<10 per 2 mm²) (34), we rarely encounter tumors with classic carcinoid morphology and mitotic rates exceeding 10 mitoses per 2 mm² (35-38). The current WHO scheme recommends that the latter be classified as LCNEC (21). Quinn et al. reported 12 lung neuroendocrine tumors with morphologic features of carcinoid and mitotic counts of >10 per 2 mm². All but one patient developed metastasis, and seven died of the tumor. Thus, they concluded that this subset of tumor appears aggressive and would be classified as LCNEC according to the

Figure 2 Small cell lung carcinoma (HE, ×20). Cell size is small. Tumor cells have scant cytoplasm so that the cellularity is high. The nuclei are round or oval. The chromatin of the nucleus is finely granular, and nucleoli are inconspicuous.

Figure 3 Borderline high-grade neuroendocrine carcinoma (HE, ×20). Cell size is larger than that of small cell lung carcinoma, but smaller than that of large cell neuroendocrine carcinoma. Tumor cells are polygonal and have a moderate amount of cytoplasm. Rosette-like structures are present. The chromatin of the nucleus is finely granular, and nucleoli are seen. Necrosis is present.
current WHO classification scheme. However, clinical and pathologic features of these tumors appear to be more in common with carcinoid tumors than LCNEC.

**LCNEC vs. NSCLC**

Adenocarcinomas with solid pattern may show a nesting pattern and large areas of necrosis, mimicking LCNEC. Central luminal spaces surrounded by tumor cells observed in adenocarcinomas with cribriform pattern may be confused with rosette-like structures of LCNEC. However, they can be differentiated from LCNEC by the absence of neuroendocrine marker expression. Basaloid squamous cell carcinoma shows nesting and/or trabecular growth patterns with peripheral palisading and large areas of necrosis, mimicking LCNEC. Some basaloid squamous cell carcinomas have very small tumor cells that can resemble those of SCLC. However, the diffuse, strong p40 and CK5/6 positivity that characterize basaloid squamous cell carcinoma is absent in LCNEC and SCLC. Conversely, unequivocal neuroendocrine differentiation by immunohistochemistry and/or EM, characteristic of most LCNEC and SCLC, is not seen in basaloid squamous cell carcinoma. Large cell carcinomas with neuroendocrine morphology and negative neuroendocrine markers are referred to large cell carcinoma with neuroendocrine morphology (LCCNM), while large cell carcinomas which do not show neuroendocrine morphology by light microscopy but do demonstrate neuroendocrine differentiation on immunohistochemistry and/or EM are referred to large cell carcinoma with neuroendocrine differentiation (LCCND). LCCNM and LCCND are not included in the LCNEC category. Although their biology has not been fully examined due to the small numbers of such entities, some studies have reported that they are as aggressive as LCNEC (8,12). The presence of morphologic overlap between LCNEC and the well-defined entities is likely reflection of its biologic heterogeneity reported by the recent molecular studies (19,20). For instance, using next-generation sequencing (NGS), Rekhtman and colleagues have identified two major and one minor subsets in LCNEC, namely SCLC-like, NSCLC-like and carcinoid-like subsets. The genomically defined subgroups were enriched in tumors with SCLC-like, NSCLC-like and carcinoid-like morphologic features, respectively, and as a group, tumors with SCLC-like molecular features were more proliferative, although there is a substantial histologic overlap between the SCLC-like and NSCLC-like subsets (19).

**Molecular features**

There are multiple studies that have shown similarities and differences in molecular alterations among high-grade neuroendocrine carcinoma (Table 1). Genome-wide high-resolution search for loss of heterozygosity (LOH) in high-grade neuroendocrine carcinomas has been conducted using SCLC and NSCLC cell lines (57,58). These studies found that LOH of some loci was mutual in SCLC and NSCLC subtypes, whereas LOH of some other loci was subtype-specific. In our study, all of SCLC and borderline high-grade neuroendocrine carcinomas showed LOH at 3p, 13q, and 5q (Figure 4), while LOH at 5q and 17p was more prevalent in SCLC and borderline cases than in LCNEC, and LOH at 9p was more frequent in LCNEC (31). As for copy number alterations, losses of 3p, 4q, 5q, and/or 13q and a gain of 5p were seen in both SCLC and LCNEC, while a gain of 3q and losses of 10q, 16q, and/or 17p were observed frequently in SCLC but not in LCNEC, and a gain of 6p occurred more frequently in LCNEC (39).

Jones et al. investigated gene expression profiles using cDNA microarrays with over 40,000 elements and were able to divide LCNECs and SCLCs into two groups according to prognosis. However, they did not correspond to LCNECs and SCLCs as defined histologically (59).

At an individual gene level, LCNEC shares TP53 and RB1 mutations with SCLC (60). However, the frequency of RB1 mutations is lower in the LCNEC than in SCLC (42). Conversely, SKT11, KRAS, KEAP1, LAMA1, PCLO, and MEGF8 mutations are more prevalent in LCNEC than in SCLC (19,42). EGFR mutations are restricted to a very minor component of both SCLCs and LCNECs (14,42,49-52), but they may be seen more frequently in combined histology. For instance, one study has reported EGFR mutations in 3 of 15 (20%) combined SCLCs with adenoscarcinoma (52). ALK, ROS1, BRAF, RET, or ERBB2 alterations are very rarely detected in both SCLC and LCNEC (1,14,42,43,49,51,55), while c-MYC amplification were observed in less than 1/3 of both SCLC and LCNEC (41,45,54). Inactivation of p16/CDKN2, via homozygous deletions, mutations or promoter hypermethylation, has been reported in LCNEC and borderline high-grade neuroendocrine carcinomas, but is vanishingly rare in SCLC (31,56,61), in which RB mutations are common and do not require p16/CDKN2 inactivation for CDK4 activation (61).

As for expression of biomarkers, Bari et al. performed high-throughput gene expression profiling in eight
Table 1 Molecular abnormalities in SCLC and LCNEC

<table>
<thead>
<tr>
<th>Variable</th>
<th>SCLC (%)</th>
<th>LCNEC (%)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CGH</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss</td>
<td>3p, 4q, 5q, 13q, 10q, 16q, 17p</td>
<td>3p, 4q, 5q, 13q</td>
<td>(39)</td>
</tr>
<tr>
<td>Gain</td>
<td>5p, 3q</td>
<td>5p, 6p</td>
<td>(39)</td>
</tr>
<tr>
<td>LOH</td>
<td>3p, 5q11, 5q21, 5q33, 10p, 10q, 13q, 17p</td>
<td>3p, 5q11, 9p, 10q, 10q, 13q, 17p</td>
<td>(40, 41)</td>
</tr>
<tr>
<td><strong>Mutation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>75–94</td>
<td>71–95</td>
<td>(1, 19, 42-46)</td>
</tr>
<tr>
<td>RB1</td>
<td>40–91</td>
<td>26–38</td>
<td>(19, 42-44-46)</td>
</tr>
<tr>
<td>CREBBP</td>
<td>17</td>
<td>6</td>
<td>(19, 47)</td>
</tr>
<tr>
<td>EP300</td>
<td>10</td>
<td>0</td>
<td>(19, 47)</td>
</tr>
<tr>
<td>MLL</td>
<td>10</td>
<td>8</td>
<td>(19, 47)</td>
</tr>
<tr>
<td>KEAP1</td>
<td>N/A</td>
<td>31</td>
<td>(19)</td>
</tr>
<tr>
<td>STK11</td>
<td>0</td>
<td>16–33</td>
<td>(43, 48)</td>
</tr>
<tr>
<td>KRAS</td>
<td>0–2</td>
<td>4–24</td>
<td>(14, 19, 41-43, 49-51)</td>
</tr>
<tr>
<td>BRAF</td>
<td>0–1</td>
<td>0</td>
<td>(1, 43, 49)</td>
</tr>
<tr>
<td>EGFR*</td>
<td>0–7</td>
<td>0–4</td>
<td>(14, 19, 42, 49, 52)</td>
</tr>
<tr>
<td>PTEN</td>
<td>2–10</td>
<td>4–13</td>
<td>(42, 43, 46, 53)</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>1–13</td>
<td>3–4</td>
<td>(1, 42, 43, 49, 50)</td>
</tr>
<tr>
<td>FGFR1</td>
<td>3–7</td>
<td>5</td>
<td>(42)</td>
</tr>
<tr>
<td>AKT1</td>
<td>0</td>
<td>0</td>
<td>(19, 50)</td>
</tr>
<tr>
<td>AKT2</td>
<td>2</td>
<td>0–4</td>
<td>(19, 42)</td>
</tr>
<tr>
<td>LAMA1</td>
<td>2</td>
<td>10</td>
<td>(42)</td>
</tr>
<tr>
<td>PCLO</td>
<td>1</td>
<td>6</td>
<td>(42)</td>
</tr>
<tr>
<td>MEGF8</td>
<td>0</td>
<td>5</td>
<td>(42)</td>
</tr>
<tr>
<td>RICTOR</td>
<td>6</td>
<td>4–5</td>
<td>(19, 42)</td>
</tr>
<tr>
<td>mTOR</td>
<td>N/A</td>
<td>1–2</td>
<td>(19, 42)</td>
</tr>
<tr>
<td>KIT</td>
<td>1–2</td>
<td>4–13</td>
<td>(1, 42, 43)</td>
</tr>
<tr>
<td><strong>Rearrangement</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALK</td>
<td>0</td>
<td>0–2</td>
<td>(14, 43, 49, 51)</td>
</tr>
<tr>
<td>RET</td>
<td>0</td>
<td>2</td>
<td>(43, 49)</td>
</tr>
<tr>
<td>ROS1</td>
<td>0</td>
<td>0</td>
<td>(43, 49)</td>
</tr>
<tr>
<td><strong>Amplification</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYC</td>
<td>18–30</td>
<td>23</td>
<td>(41, 45, 54)</td>
</tr>
<tr>
<td>ERBB2</td>
<td>0–36</td>
<td>0–27</td>
<td>(42, 49, 55)</td>
</tr>
<tr>
<td><strong>p16/CDKN2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homozygous deletion</td>
<td>0–1</td>
<td>N/A</td>
<td>(55, 56)</td>
</tr>
<tr>
<td>Methylation</td>
<td>0</td>
<td>30</td>
<td>(31)</td>
</tr>
</tbody>
</table>

*, combined small cell carcinomas are excluded. SCLC, small cell lung carcinoma; LCNEC, large cell neuroendocrine carcinoma; N/A, not applicable.
LCNEC and eight SCLC samples and revealed relative up-regulation of CDX2 and villin in LCNEC and that of BAI3 in SCLC (62).

These similarities and differences in molecular profiles between LCNEC and SCLC can be explained by the heterogeneous biology of LCNEC that has recently been elucidated by two studies (19,20). Fernandez-Cuesta and colleagues analyzed 60 LCNEC cases and confirmed the presence of two well-defined groups of LCNEC: a SCLC-like group, carrying MYCL1 amplifications and concurrent RB1 and TP53 mutations; and an adenocarcinoma/squamous cell carcinoma-like group, harboring p16/CDKN2A deletions, TTF-1 amplifications, and frequent mutations in KEAP1 and STK11 (20). Similarly, in the aforementioned study, Rekhtman and colleagues analyzed 45 LCNEC cases with NGS of 241 cancer genes and found two major molecular subsets along with a minor subset. The major subsets consisted of SCLC-like LCNEC (n=18), characterized by TP53 and RB1 co-mutation/loss and other SCLC-type alterations, including MYC amplification, and NSCLC-like LCNEC (n=25), characterized by lack of concurrent TP53 and RB1 alterations and nearly universal occurrence of NSCLC-type mutations (SKT11, KRAS, and/or KEAP1). In addition, they identified two carcinoid-like tumors, characterized by MEN1 mutations and low mutation burden (19).

**Therapy**

Dresler et al. reported no survival benefits from postoperative chemotherapy, radiation therapy, or both in patients with resected LCNEC (63). Iyoda et al., however, have shown that adjuvant chemotherapy improved survival in stage I LCNEC but not in stage II or III disease in a retrospective study (64). The study by Rossi et al. reported the role of a SCLC-based chemotherapy in an adjuvant setting for stage I–III diseases (11). Iyoda et al., in their recent prospective study, concluded that adjuvant chemotherapy, consisting of platinum/etoposide, after surgery appeared preventing recurrence in patients with completely resected LCNECs (65). While surgery with a curative intent and completeness of resection may be advocated for the treatment of patients with LCNEC, they will likely benefit from adjuvant chemotherapy with a SCLC regimen (66).

In the advanced stage setting, while response rates of approximately 50% and up to 80% have been demonstrated in prospective studies utilizing platinum/etoposide in patients with extensive stage SCLC, chemosensitivity of LCNEC to this regimen is somewhat controversial (14-18,67). It may be attributed in part to the heterogeneous morphology and biology of LCNEC. In addition, the difficulty in diagnosing LCNEC on biopsy specimens may lead to the conflicting results. Among several retrospective studies, Sun et al. reviewed 45 patients with advanced LCNEC and concluded that advanced LCNEC can be appropriately treated in the similar manner to SCLC rather than NSCLC (18). In this cohort, eleven patients received first-line platinum/etoposide, and the remaining 34 patients received various types of NSCLC regimens. The response rate to the SCLC regimen was 73%, which was higher than that (50%) to NSCLC regimen. The median overall survival was 16.5 and 9.2 months in the SCLC and NSCLC regimen groups, respectively. Of note, pathological data were extracted from medical records; however, it is not clear how the pathological diagnosis of LCNEC were rendered. Similarly, Shimada et al. found that overall response rate to the initial chemotherapy or chemoradiotherapy and the survival outcomes of high-grade neuroendocrine carcinoma—probable LCNE were comparable to those of SCLC. In their study, 25 patients, who had been diagnosed to have high-grade neuroendocrine carcinoma—probable LCNE by review of biopsy specimens and had undergone chemotherapy or chemoradiotherapy as the initial therapy, were compared with 180 patients with SCLC (17). Yamazaki et al. have also reported that the response rate of LCNEC to platinum-based chemotherapies was comparable to that of SCLC in their review of 20 patients with stage IIIA–IV LCNEC. In this study, pathological
diagnosis of LCNEC was confirmed with operation or autopsy. The patients received a combination of platinum/etoposide (n=9), platinum, vindesine and mitomycin (n=6), platinum and vindesine (n=4), or platinum alone (n=1), and the objective response rate was 50% (67). Conversely, Naidoo et al., in their review of 49 patients with pathologically confirmed stage IV LCNEC, concluded that LCNEC may not respond to platinum/etoposide as robustly as reported cases with extensive stage SCLC (14).

In this study, the patients were identified by a search of an institutional electronic database, and available tissue was subjected to pathology re-review to confirm the diagnosis of LCNEC. There are a few prospective studies on the efficacy of platinum/etoposide doublet chemotherapy for LCNEC. Prospective, multicenter, single-arm, phase II trial of platinum/etoposide doublet chemotherapy in 42 patients with stage IIIB or IV LCNEC reported partial response in 34% of 29 patients in whom the diagnosis of LCNEC was confirmed by the centralized pathology review, and concluded that the outcome of advanced LCNEC treated with platinum/etoposide doublet chemotherapy was similar to that reported in extensive SCLC (16). Conversely, Niho et al., in their prospective, multicenter, single-arm, phase II study in patients with stage IIIB or IV LCNEC, showed that combined chemotherapy with irinotecan and platinum in patients with advanced LCNEC resulted in inferior overall survival than those with SCLC (15). In this study, the response rate was 47% for patients with LCNEC and 80% for patients with SCLC (P=0.082). The median survival time was 12.6 months in the LCNEC group and 17.3 months in the SCLC group (P=0.047). Of note, in these two prospective studies, the pathological diagnosis was confirmed by independent review by the pathology panel members followed by consensus diagnosis, and one-fourth of the cases with the original diagnosis of LCNEC were reclassified, elucidating the difficulty in the histologic classification of high-grade neuroendocrine carcinomas (15,16). Interestingly, in the aforementioned study by Rekhtman et al., three of four patients with SCLC-like LCNEC responded to platinum based cytotoxic chemotherapy, while none of six patients with NSCLC-like LCNEC (19). These lines of evidence confirm the heterogeneous morphology and biology of LCNEC.

**Conclusions**

Growing evidence suggests that LCNEC is a morphologically and biologically heterogeneous group of high-grade neuroendocrine carcinomas. There are morphological borderline cases between SCLC and LCNEC leading to the difficulty in classifying some high-grade neuroendocrine carcinomas into the two entities. Among these borderline tumors, some harbor molecular alterations similar to those of SCLC and others to LCNEC. Furthermore, recent molecular studies have revealed a few distinct subsets of LCNEC. Of those, the SCLC-like subset appears to exhibit SCLC-like morphology and respond to chemotherapeutic regimens for SCLC, while the NSCLC-like subset does not. The findings may explain the conflicting reports on the sensitivity of LCNEC to the SCLC regimens. Additional large cohort studies on the biology of high-grade neuroendocrine carcinomas are warranted and will aid establishing novel approaches to clinical managements of patients with LCNEC.

**Acknowledgements**

None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

**References**

epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.


Cite this article as: Hiroshima K, Mino-Kenudson M. Update on large cell neuroendocrine carcinoma. Transl Lung Cancer Res 2017;6(5):530-539. doi: 10.21037/tlcr.2017.06.12